InsiderTrades.com logo
Trump’s Back, but DC’s Coming for Your Money!
From Genesis Gold Group   |   Ad
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov
Diane C. Young net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Diane Young Biography and Net Worth

SVP of Celldex Therapeutics
Dr. Young joined Celldex in July 2019 as Senior Vice President and Chief Medical Officer. Prior to joining Celldex, she was the Chief Medical Officer of GTx, Inc., a public biopharmaceutical company focused on developing therapeutics that target nuclear hormone receptors. Previously, she spent 13 years at Novartis Oncology in senior leadership roles in global clinical development and medical affairs. As the Head of Oncology Clinical Development, she directed the clinical programs leading to successful regulatory approvals for EXJADE®, GLIVEC®, FEMARA®, AFINITOR®, RYDAPT®, JAKAVI® and FARIDAK® among others. Prior to Novartis, Diane held senior leadership positions in clinical development at the R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, Hoffman-La Roche and Sandoz. Dr. Young received her A.B. in Biochemical Sciences at Harvard University and her M.D. from Harvard Medical School. Her postdoctoral training included an Internal Medicine Residency at Johns Hopkins Hospital and Vanderbilt Hospital, followed by an Oncology Fellowship at the Dana-Farber Cancer Institute. She is board certified in Internal Medicine and Medical Oncology.

What is Diane C. Young's net worth?

The estimated net worth of Diane C. Young is at least $49,808.25 as of June 7th, 2024. Dr. Young owns 2,115 shares of Celldex Therapeutics stock worth more than $49,808 as of November 17th. This net worth approximation does not reflect any other assets that Dr. Young may own. Additionally, Dr. Young receives a salary of $696,450.00 as SVP at Celldex Therapeutics. Learn More about Diane C. Young's net worth.

How old is Diane C. Young?

Dr. Young is currently 67 years old. There are 8 older executives and no younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics is Prof. Joseph P. Schlessinger Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 79 years old. Learn More on Diane C. Young's age.

What is Diane C. Young's salary?

As the SVP of Celldex Therapeutics, Inc., Dr. Young earns $696,450.00 per year. There are 2 executives that earn more than Dr. Young. The highest earning executive at Celldex Therapeutics is Mr. Anthony S. Marucci M.B.A., Founder, President, CEO & Director, who commands a salary of $1,270,000.00 per year. Learn More on Diane C. Young's salary.

How do I contact Diane C. Young?

The corporate mailing address for Dr. Young and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Diane C. Young's contact information.

Has Diane C. Young been buying or selling shares of Celldex Therapeutics?

Diane C. Young has not been actively trading shares of Celldex Therapeutics within the last three months. Most recently, Diane C. Young sold 45,000 shares of the business's stock in a transaction on Friday, June 7th. The shares were sold at an average price of $35.26, for a transaction totalling $1,586,700.00. Following the completion of the sale, the senior vice president now directly owns 2,115 shares of the company's stock, valued at $74,574.90. Learn More on Diane C. Young's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.

Information on this page was last updated on 11/11/2024.

Diane C. Young Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/7/2024Sell45,000$35.26$1,586,700.002,115View SEC Filing Icon  
11/12/2021Sell4,600$42.94$197,524.00View SEC Filing Icon  
6/11/2020Buy2,115$4.73$10,003.952,115View SEC Filing Icon  
See Full Table

Diane C. Young Buying and Selling Activity at Celldex Therapeutics

This chart shows Diane C Young's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $23.55
Low: $23.49
High: $25.89

50 Day Range

MA: $31.89
Low: $23.55
High: $44.16

2 Week Range

Now: $23.55
Low: $23.49
High: $53.18

Volume

1,249,780 shs

Average Volume

1,057,140 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6
Trump’s Back, but DC’s Coming for Your Money!
From Genesis Gold Group   |   Ad
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov